Therapeutic Solutions International Reports Reduction of Brain Inflammation/Depression Associated Biochemical Pathway Using QuadraMune™ in Animal Studies
Continued Basic Science Experiments Support New Patent Filing Covering Suppression of Indolamine 2,3 Deoxygenase Pathway by QuadraMune™
OCEANSIDE, California, June 15, 2020 /PRNewswire/ -- Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announced today the filing of a new patent covering suppression of the indolamine 2,3 deoxygenase (IDO) pathway by QuadraMune™ administration.
In the study, mice were administered lipopolysaccharide (LPS), a compound known to stimulate inflammation, in order to replicate inflammation-associated depression. Mice receiving LPS suffered a reduction in memory activity, as quantified using the Morris Water Maze test.
Administration of QuadraMune™ significantly inhibited inflammation associated with memory impairment, as well as reduced levels of kynurenine. Elevation of kynurenine is associated with activation of indolamine 2,3 deoxygenase, an enzyme associated with inflammation and depression [1].
"The current data support the possibility of QuadraMune™ being used as an adjuvant to numerous immune therapies whose efficacy is currently inhibited by the depression-inducing and immune blocking effects of the indolamine 2,3 deoxygenase enzyme," said Dr. James Veltmeyer, Chief Medical Officer and co-inventor of the current patent. "Many times, when you activate the immune system, cells in the body, and in the brain, start producing the enzyme indolamine 2,3 deoxygenase, whose role is to restrain the immune system, and for reasons unknown, causes depression. By manipulating this enzyme through natural means, we are optimistic that we can enhance the efficacy of numerous immune modulatory treatments for viral and neoplastic conditions."
Dr. Thomas Ichim, Board Member of Therapeutic Solutions International, has been working on this enzyme since 2013 when he published in the peer-reviewed literature regression of breast cancer using RNA interference to block its expression [2].
"From a commercialization perspective we are truly optimistic about the implications of the current results, which may require us to consider expanding our clinical trial programs," said Timothy Dixon, President, and CEO of the Company. "The IDO enzymatic pathway is not only extremely interesting from a medical perspective, but companies working on manipulating this pathway have previously entered Big Pharma deals with potential values in excess of $1 billion [3]. In contrast to other programs that utilize synthetic approaches, QuadraMune™, which is comprised of natural ingredients and is available as a nutraceutical, may possess numerous advantages for accelerated commercialization."
About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one's immune system. The Company's corporate website is at www.therapeuticsolutionsint.com and our e-commerce is at www.youcanordernow.com and for additional info on QuadraMune™ visitwww.areyoucovidmune.com/covidmune/.
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
[1] Lanser et al. Inflammation-Induced Tryptophan Breakdown Is Related With Anemia, Fatigue, and Depression in Cancer. Front Immunol . 2020 Feb 21;11:249. https://www.frontiersin.org/articles/10.3389/fimmu.2020.00249/full
[2] Zheng et al. Silencing IDO in Dendritic Cells: A Novel Approach to Enhance Cancer Immunotherapy in a Murine Breast Cancer Model. Int J Cancer. 2013 Feb 15;132(4):967-77
Contact Details:
Timothy Dixon
Therapeutic Solutions International, Inc.
[email protected]
+1(760) 295-7208
- Company Files New Patent Application on QuadraMune™ for Suppression of Indolamine 2,3 Deoxygenase Pathway
SOURCE Therapeutics Solutions International, Inc.
Share this article